Well Researched

TB-500

Ac-LKKTETQ | Synthetic Fragment (17-23) of Thymosin Beta-4

TB-500 is a synthetic 7-amino acid fragment (Ac-LKKTETQ) corresponding to the active actin-binding region (positions 17-23) of thymosin beta-4. Originally developed for veterinary use in horses, this fragment retains tissue repair and anti-inflammatory properties while being more stable than the full peptide. Banned by WADA for its performance-enhancing effects

Daily dose

2-5mg

Frequency

2-3x/week

Cycle length

6-8 weeks

Storage

2-6°C

Key benefits

Superior systemic tissue repair, accelerated healing of muscles, tendons, ligaments, and organs. Enhanced cell migration and angiogenesis for comprehensive regenerative effects.

How it works

TB-500 acts as the principal actin-sequestering protein in mammalian cells, regulating cell migration, promoting angiogenesis, reducing inflammation, and activating stem cell differentiation for accelerated healing and tissue regeneration.

Dosage protocols

Goal

General tissue repair

Dose

2-3mg · 2x weekly

Route

SubQ or IM

Goal

Serious injury recovery

Dose

4-5mg · 3x weekly

Route

SubQ near injury site

Goal

Athletic enhancement

Dose

2-3mg · 2x weekly

Route

SubQ

Goal

Chronic conditions

Dose

3-4mg · 2-3x weekly

Route

SubQ or IM

Research indications

tissue Repair

Muscle Regeneration — Accelerated healing of muscle fibers, reduced recovery time from muscle injuries, and enhanced muscle tissue repair through improved cell migration and differentiation.

Tendon & Ligament Healing — Promotes connective tissue repair, reduces scar formation, and improves biomechanical properties of healing tendons and ligaments.

Wound Healing — Enhanced dermal wound closure, improved angiogenesis, and reduced inflammation in both acute and chronic wound healing scenarios.

athletic Recovery

Exercise Recovery — Faster recovery from intense training, reduced exercise-induced muscle damage, and improved adaptation to training stress.

Injury Prevention — Strengthened connective tissues, improved tissue resilience, and reduced risk of overuse injuries through enhanced tissue quality.

Performance Enhancement — Improved muscle fiber quality, enhanced endurance capacity, and better overall tissue function supporting athletic performance.

neurological

Neuroprotection — Protective effects against neuronal damage, reduced neuroinflammation, and support for nervous system recovery following injury.

Spinal Cord Support — Enhanced recovery in spinal cord injury models through neuroprotective and anti-inflammatory mechanisms.

Brain Health — Potential benefits for brain injury recovery, improved neuroplasticity, and protection against neurodegenerative processes.

Administration

injectable

topical

Interactions

Synergistic

BPC-157 — Complementary healing mechanisms with enhanced tissue repair when used together

Compatible

Ipamorelin — TB-500 may enhance tissue sensitivity to growth hormone effects

Synergistic

CJC-1295 — TB-500 tissue repair combined with GH-releasing effects for comprehensive recovery

Synergistic

IGF-1 — Enhanced muscle and tissue regeneration through complementary growth pathways

Compatible

GHRP-6 — No known negative interactions, potential for enhanced recovery

Compatible

Melanotan II — No interaction expected - TB-500 promotes tissue repair via actin regulation, Melanotan II acts on melanocortin receptors. Completely different receptor families with no pathway overlap.

Safety notes

Use sterile injection technique to prevent infection

Mild injection site reactions are normal and temporary

Consult healthcare provider if on immunosuppressive medications

Not recommended during active cancer treatment

Avoid during pregnancy or breastfeeding

WADA prohibited - not for competitive athletes

Research studies

Cardiac Tissue Regeneration (2016)

Human Clinical Trial | IV administration | Improved cardiac function

Pilot study showed TB-500 pre-treated endothelial progenitor cell transplantation improved left ventricular function by >50% in post-MI patients.

Muscle Fiber Regeneration (2015)

Mouse Model | 6 months | Enhanced skeletal muscle repair

TB-500 improved skeletal muscle fiber regeneration in dystrophin-deficient mice, showing potential for muscular dystrophy treatment.

Corneal Healing Research (2014)

Human Phase 2 | Eye drops | Improved dry eye symptoms

Topical TB-500 eye drops significantly improved signs and symptoms of moderate to severe dry eye with lasting effects beyond treatment period.

Dermal Wound Healing Study (2012)

Human Phase 2 | Topical application | Accelerated healing rate

TB-500 demonstrated significant acceleration in wound healing rates in patients with chronic pressure ulcers and venous stasis ulcers compared to placebo controls.

Related compounds

BPC-157 Thymosin Beta-4 Wolverine Stack KLOW Protocol